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ABSTRACT
Surgical repair of large muscular defects requires the use of autologous graft transfer or prosthetic
material. Naturally derived matrices are biocompatible materials obtained by tissue decellularization
and are commonly used in clinical practice. Despite promising applications described in the litera-
ture, the use of acellular matrices to repair large defects has been only partially successful, highlight-
ing the need for more efﬁcient constructs. Scaffold recellularization by means of tissue engineering
may improve not only the structure of the matrix, but also its ability to functionally interact with
the host. The development of such a complex construct is challenging, due to the complexity of the
native organ architecture and the difﬁculties in recreating the cellular niche with both proliferative
and differentiating potential during growth or after damage. In this study, we tested a mouse dec-
ellularized diaphragmatic extracellular matrix (ECM) previously described by our group, for the gen-
eration of a cellular skeletal muscle construct with functional features. The decellularized matrix was
stored using different conditions to mimic the off-the-shelf clinical need. Pediatric human muscle
precursors were seeded into the decellularized scaffold, demonstrating proliferation and differentia-
tion capability, giving rise to a functioning three-dimensional skeletal muscle structure. Furthermore,
we exposed the engineered construct to cardiotoxin injury and demonstrated its ability to activate a
regenerative response in vitro promoting cell self-renewal and a positive ECM remodeling. Functional
reconstruction of an engineered skeletal muscle with maintenance of a stem cell pool makes this a
promising tool toward future clinical applications in diaphragmatic regeneration. STEM CELLS
TRANSLATIONAL MEDICINE 2019;00:1–12
SIGNIFICANCE STATEMENT
In the present work, a storable and ready-to-use decellularized diaphragm-derived extracellular
matrix (ECM) was used as cell support to generate a self-renewing skeletal muscle xenogeneic
construct, as a combination of a mouse-derived ECM and human progenitor cells. This work rep-
resents a step forward toward the generation of tissue engineering xenograft for skeletal muscle
clinical applications.
INTRODUCTION
Surgical treatment of a variety of pathological con-
ditions, includingmalformations, congenital defects,
post-traumatic muscle loss, and postsurgery tissue
ablation, remains challenging. Conventional treat-
ments involving primary repairs, autograft and free
ﬂaps, or prostheticmaterial have several limitations,
including strength, growth, and susceptibility to
infections [1–4]. On the other hand, skeletal mus-
cle tissue regeneration has been widely investi-
gated and different tissue engineering approaches
have been used [5–8]. Tissue engineering aims
to regenerate damaged tissue by recreating a
microenvironment similar to the original. This
purpose requires the right culture setting (e.g.,
oxygenation and mechanical stimuli), appropriate
progenitor cells able to differentiate into the
desired lineage and scaffolds that foster cell–
matrix interaction and tissue regeneration. Up to
now, tissue engineering has been successfully
applied for the regeneration of several organs
such as urinary bladder [9, 10], vagina [11], tra-
chea [12], heart [13, 14], and skin [15]. Skeletal
muscle is more challenging and the possibility of
recreating alternative functional transplantable
muscle that could be efﬁciently used for patients
remains an unmet clinical need. Skeletal muscle
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is a ﬁnely organized tissue in which myoﬁber correct organization
and coordination ensures muscle contraction and relaxation,
thereby enabling tissue function. The thoracic diaphragm is a
complex muscle organ essential to support respiration [16, 17].
The diaphragm also exerts nonrespiratory functions, including the
promotion of venous return, lymphatic sieving, and gastroesopha-
geal reﬂux restriction [18–22]. All these functions are supported
by a unique anatomy: diaphragm is ﬂat, with a central tendon and
outward radiating myoﬁbers [23]. Traumatic events or congenital
defects (as congenital diaphragmatic hernia [CDH]) are phenom-
ena that affect diaphragm integrity and functions, leading to the
herniation of the abdominal organs into the thoracic cavity. In
CDH, diaphragm defect size is one of the most important aspects
in the choice of the appropriate approach to repair the hernia [24].
Primary repair is the preferred method but is not possible in larger
defects. In such cases, a patch of polytetraﬂuoroethylene (PTFE) is
usually applied [25]. However, reherniation occurs in 28%–50% of
cases, generally around 12months after implantation [26–28],
compelling patients to undergo multiple surgeries and increasing
risks and drawbacks. The use of biologically derived scaffolds for
hernia repair such as acellular dermal matrix or intestinal submu-
cosa, has been shown to be successful [29], but clinical study did
not ﬁnd a difference in the rate of recurrences between acellular
matrix and PTFE [26].
Extracellular matrix (ECM) biologic scaffolds are usually
derived via mammalian tissue decellularization, a process that
removes cells while retaining the architecture and composition
of the native ECM. This technique allows not only to avoid
adverse antigenic response once decellularized ECM is impla-
nted in vivo in allogenic settings, but also to promote the
engraftment of seeded and host-derived invading cells [8, 30].
Recently, we extensively characterized the ECM obtained from
decellularized mouse diaphragm and demonstrated the ability
of this natural-derived scaffold to recruit host muscle precursor
cells (MPCs) when orthotopically implanted in wild and atrophic
mouse models [31]. This scaffold showed signiﬁcant characteris-
tics, such as the preservation of decellularized myoﬁber struc-
ture and composition, biomechanical features similar to native
diaphragms, positive immunological properties, and angiogenic
activity [32]. For these reasons, we believe that it can be consid-
ered an excellent candidate scaffold to support the in vitro gen-
eration of a diaphragmatic muscle construct.
In recreating an in vitro engineered tissue, the choice of the
most appropriate cell source for scaffold recellularization is of para-
mount importance. The ideal cell population should be (a) derived
from an easily accessible source, (b) capable of proliferation and
self-renew, in order to guarantee a complete scaffold repopulation,
and (c) able to differentiate giving rise to the cell types necessary
for tissue function [33]. Human MPCs (hMPCs) are progenitor cells
committed toward muscle lineage that can be easily isolated from
small humanmuscle biopsies and hold the ability to grow in culture
maintaining self-renewal and proliferation ability along with myo-
genic potential [34, 35]. Given their speciﬁcity and commitment,
hMPCs have been chosen as cell source in several muscle tissue
engineering studies [36, 37].
In the present work, we described a storage protocol for
the long-term preservation of mouse decellularized diaphragm-
derived ECM (dECM), which was then repopulated with pediat-
ric hMPCs. Our proof of principle study was focused on the
in vitro engineering and functional characterization of a construct
for future diaphragmatic tissue regeneration. Finally, in order to
prove the ability of self-renewing, we applied an injury to the
xenograft and demonstrated its ability to activate a regeneration
process that involves proliferation and differentiation of engrafted
progenitor cells and also modiﬁcation of the cellular niche.
MATERIALS AND METHODS
Diaphragm Muscle Decellularization
Diaphragm muscles obtained from 3-month-old C57BL/6j mice
(protocol number 1103/2016 approved by animal wellness
local ethics committee Organismo per il Benessere Animale,
Padova; all experiments were performed in accordance with
relevant guidelines and regulations) were washed two times in
1× sterile phosphate-buffered saline (PBS, Gibco, Fisher Scien-
tiﬁc, Monza, Italy) and then transferred in deionized water in
order to start the decellularization process. Diaphragms were
processed with three detergent-enzymatic treatment (DET)
cycles in order to obtain a complete cell removal. Each DET
cycle was composed of deionized water at 4C for 24 hours,
4% sodium deoxycholate (Sigma, Merck KGaA, Darmstadt,
Germany) at room temperature (RT) for 4 hours, and 2,000 kU
DNase-I (Sigma, Merck KGaA, Darmstadt, Germany) in 1 M
NaCl (Sigma, Merck KGaA, Darmstadt, Germany) at RT for
3 hours [31]. After decellularization, matrices were washed for
at least 3 days in deionized sterile water and immediately ana-
lyzed or preserved in different storage conditions.
Diaphragm ECM Storage
Five different conditions were tested to ﬁnd the best compro-
mise between matrix preservation and longest storing period
possible: fresh (dECM analyzed immediately after DET proto-
col, n = 9); 2w4C (dECM preserved for 2 weeks at 4C in 1×
PBS supplemented with 3% pen/strep, n = 9); 2m4C (dECM
preserved for 2 months at 4C in 1× PBS supplemented with
3% pen/strep, n = 9); 2wLN (dECM preserved for 2 weeks in
liquid nitrogen in freezing medium, n = 9); 2mLN (dECM pre-
served for 2 months in liquid nitrogen in freezing medium,
n = 9). In 2w4C and 2m4C conditions, 1× PBS supplemented
with 3% of pen/strep was changed every 3 days in order to
maintain antibiotic coverage; in 2wLN and 2mLN conditions,
freezing medium was composed of 10% Dulbecco’s modiﬁed
Eagle’s medium (DMEM) high glucose (4.5 g/l D-glucose, Gibco-
Fisher Scientiﬁc), 20% dimethyl sulfoxide (DMSO, Sigma–Aldrich),
and 70% fetal bovine serum (FBS, Gibco-Fisher Scientiﬁc). Speciﬁ-
cally, dECM were immersed in 1 ml of freezing medium, slowly
cooled in cryoboxes overnight, and then transferred to liquid
nitrogen. Stored dECM were defrosted the day before performing
experiment, washed in 1× PBS supplemented with 3% pen/strep
and preserved at 4C for up to 12hours.
Diaphragm ECM Components Quantiﬁcations
Wet samples for quantiﬁcation were snap frozen before use.
Collagen, sulfated glycosaminoglycan (sGAG), and elastin content
on decellularized diaphragms were quantiﬁed using, respectively,
the Sircol™ Collagen Assay, Blyscan GAG Assay Kit, and Fastin Elas-
tin Assay Kit (all from Biocolor, Carrickfergus, United Kingdom)
under manufacturer’s instruction.
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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Histology and Immunoﬂuorescence
Tissue samples were ﬁxed in 4% paraformaldehyde (PFA, Sigma–
Aldrich) for 1 hour at 4C. Histology was evaluated using frozen
sections (8–10 μm thick), stained with hematoxylin and eosin kit
for rapid frozen sections, Masson’s Trichrome (MT) with aniline
blue kit or Alcian blue pH 2.5 kit (all from Bio-Optica, Milan, Italy)
under manufacturer’s instruction. For immunoﬂuorescence ana-
lyses, sections were incubated with primary antibodies (1 hour at
37C or overnight at 4C), washed, and then incubated for 1 hour
at 37C with labeled Alexa Fluor secondary antibodies, as listed in
Supporting Information Table S1. Finally, nuclei were counterstained
with ﬂuorescent mounting medium plus 100ng/ml 40,6-diamidino-
2-phenylindole (Sigma–Aldrich). For each diaphragm, random pic-
tures were collected with an inverted microscope.
Transmission Electron Microscopy
Samples for transmission electron microscopy were ﬁxed in 4%
PFA for 1 hour and then with 0.25% glutaraldehyde (Sigma–
Aldrich) in 0.1 M sodium cacodylate buffer overnight. After
wash, small portions were postﬁxed in osmium tetroxide 1% for
1 hour at 4C and then embedded in Epon 812 resin. Ultrathin
sections, obtained with a Reichert-Jung Ultracut ultramicro-
tome, were recovered on slot grids and counterstained with
uranyl acetate and lead citrate. The samples were examined
with a FEI Tecnai G2 transmission electron microscope operat-
ing at 100 kV. Images were captured with a Veleta (Olympus
soft Imaging System, Segrate, Milan, Italy) digital camera.
Human Pediatric MPCs Isolation, Expansion, and Cell
Cycle Length Estimation
Skeletal muscle samples were obtained from Pediatric Surgery
Clinic (Azienda Ospedialiera di Padova, Padua, Italy) and Orthopedic
Clinic, University of Padova (Padova, Italy). Patient tissues were col-
lected after written informed consent following the protocols num-
ber 2682P and number 3030P, approved by Local Ethics Committee
(Comitato etico per la sperimentazione clinica dell’Azienda
Ospedaliera di Padova). From muscle biopsies, cells were isolated
using a previously described protocol [34]. Brieﬂy, the samples
(n =7) were minced in small pieces (1–2 mm3) and incubated with
3ml of 0.2% (wt/vol) collagenase I for 90minutes at 37C. The reac-
tion was stopped by adding washing medium (DMEM low glucose,
20% FBS, 1% P/S) and the samples were then centrifuged and incu-
bated in 2 ml of 0.05% trypsin–EDTA for 60minutes at 37C. Wash-
ing mediumwas added to stop the reaction and the cell suspension
was ﬁltered ﬁrst through 70μm and then 40μm cell strainers. After
centrifugation, 3 ml of lysis buffer was added for 5 minutes to lyse
red blood cells and then stopped with washing medium. The cell
suspension was centrifuged and the pellet was resuspended in pro-
liferative medium (PM) in a well of a 6-wells culture plate. PM is
composed of DMEM low glucose (1 g/l D-glucose, Gibco-Fisher
Scientiﬁc) with 20% FBS, 10−6 M dexamethasone (Sigma–Aldrich),
10 ng/ml bFGF (R&D System, Minnesota, United States), 10 μg/ml
insulin (Humulin Eli Lilly, Indiana, United States), and 1% pen/strep.
During expansion, hMPCs were cultured in PM and kept at 37C,
5% CO2 with an oxygen tension of 20% in a humidiﬁed incubator.
For myogenic differentiation, hMPCs at conﬂuence were cultured
for 96hours in 24-wells tissue culture plates in fusion medium
(FM), composed of α MEM (Gibco-Fisher Scientiﬁc) supple-
mented with 2% HS, 10 μg/ml insulin, and 1% pen/strep. For cell
cycle length estimation, hMPCs isolated from three different
biopsies were plated in a 24-wells plate and after 72 hours of cul-
ture the cell number was determined. Each sample was assessed




log N72h=N0hð Þ ð1Þ
in which g is the generation time during the logarithmic phase
of the growth curve, N72 h is the cell number at 72 hours and
N0 h is the cell number at time 0 [38].
Flow Cytometry Analysis and Immunoﬂuorescence
Cell surface antigen expression was analyzed by ﬂow cytometry
on cells detached with trypsin–EDTA treatment at passages
3 and 5 (n = 7). The antibodies used were: CD34 FITC, CD56 PE
(both from BD Bioscience, Milan, Italy), 7-aminoactinomycinD
was used as viability assay.
For immunoﬂuorescence, both proliferating and differentiated
cells from three different samples at passage 5 were incubated for
1 hour at 37C with labeled Alexa Fluor secondary antibodies, as
listed in Supporting Information Table S1. Nuclei were counter-
stained with HOECHST (Life Technologies, Thermo Fisher, Milan,
Italy, dilution 1:10,000). To quantify myoblast fusion, the myogenic
index (MI), deﬁned as the number of nuclei residing in MYHC+ cells
containing three or more nuclei divided by the total number of
nuclei, was calculated from ﬁve random ﬁelds of each sample [39].
Diaphragm ECM Recellularization
Mouse dECM stored in different conditions were used for the
recellularization procedure. We performed n= 7 total experiments,
n =5 with fresh or 2w4C stored samples, and n=2 with 2mLN
stored diaphragms (this last condition is showed in Supporting
Information Fig. S1). Decellularized diaphragms were divided in
four patches of approximately 35mm2 (excluding the cruralmuscle).
Each one was ﬁxed with four little pins on a rubber support and
placed into a well of a 6-wells plate. Human MPCs, previously
expanded for 5 or 6 passages, were resuspended in 15μl of human
cord blood platelet gel supernatant (PGS) [40] and injected into the
dECM at a density of 5×105 cells per patch. Decellularized dia-
phragms were used as controls. After 2 hours from the seeding,
8 ml of PM were added to each well, in order to completely cover
the scaffolds. The PM was maintained for 4 days, then changed
every other day before being replaced by FM, which was kept until
the last experimental day. The cultures were analyzed after 4, 7,
12, or 21days.
Evans Blue Injection
Thirty microliters of Evans blue dye (Sigma) were injected into
a decellularized hemi-diaphragm ﬁxed on a rubber support
using a 33G needle Hamilton syringe, as shown in Supporting
Information Movie S2. This procedure was used in pilot experi-
ments to verify the injection efﬁciency.
Picogreen Assay
Recellularized samples were collected and immediately frozen in
liquid nitrogen, then transferred at −80C at least for 48 hours.
Decellularized scaffolds were used as negative control and cells
cultured on plastic as positive control. Samples were digested in
a Proteinase K solution in phosphate buffer saline (PBS) buffer.
PBS buffer was composed of: 20mM Na2HPO4, 30mM NaH2PO4
monohydrate, 5 mM Na2EDTA in deionized water; the pH was
www.StemCellsTM.com © 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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adjusted at 7.1 and the solution was then sterilized in autoclave at
121C for 15minutes. Proteinase K (Invitrogen, Thermo Fisher,
Milan, Italy) was diluted in PBS buffer at the ﬁnal concentration of
0.5 mg/ml. Each sample was immerged in 300 μl of digestion solu-
tion and incubated at 65C overnight. Once the samples were
completely digested, they were transferred into a black 96 wells-
plate (Nunc MicroWell 96-Well Optical-Bottom Plates with Poly-
mer Base, nontreated, Nunc, Thermo Fisher, Mila, Italy), and the
DNA was quantiﬁed using Quant-iT PicoGreen dsDNA Assay Kit
(Invitrogen), under manufacturer’s instruction. The standard
solution provided by the kit was used to create the standard
curve. The ﬂuorescent signal corresponding to the DNA amount
was detected using VICTOR2 1420 Multilabel Counter (Perkin
Elmer, Massachusetts, United States). Excitation λ = 485 nm and
emission λ = 535 nm.
Western Blot
Decellularized and recellularized mouse dECM, fresh diaphragm,
and hMPCs were solubilized in 1 ml of T-PER Tissue Protein
Extraction Reagent (Thermo Fisher Scientiﬁc) and homogenized
using TissueLyser (Qiagen, Hilden, Germany), according to man-
ufacturer instructions. Then, equal amounts of protein extracts
(25μg) were resolved by SDS-PAGE gels (4%–12%, 3%–8%) and
transferred to nitrocellulose transfer membrane (Advansta,
California, United State). Membranes were blocked with Blotto
nonfat dry milk (Santa Cruz, California, United State) for at least
1 hour at RT and then incubated overnight at 4C under con-
stant shaking with primary antibodies listed in Supporting Infor-
mation Table S1. Membranes were next incubated with
peroxidase-labeled secondary antibodies (Supporting Informa-
tion Table S1), visualized using ECL Select, and exposed to
Amersham Hyperﬁlm ECL (GE Healthcare, Milan, Italy).
Calcium Transient Assay
Recellularized samples of dECM or human MPC cells plated on
13mm coverslips were loaded with 20μM Fluo4_AM (Thermo
Fisher Scientiﬁc) by incubation at 37C for 30minutes in Optimem
Medium (Life Technologies) containing 0.04% Pluronic F-127 (Merck
KGaA, Darmstadt, Germany), and washed with medium. Loaded
samples were transferred under a TCS-SP5-RS confocal microscope (
Leica, Wetzlar, Germany) equipped with a 20× objective (NA, 1.0).
Laser emission at 488nm was used for stimulation and emitted cell
ﬂuorescence at 530nm was acquired, as basal value. Time frame
acquisition of 491milliseconds was used. Samples were then chemi-
cally stimulated with freshly prepared solution of ATP (1 mM), and
emitted ﬂuorescence acquired to record transient alteration in cyto-
solic calcium levels.
Cardiotoxin Injury of Recellularized ECM
Cardiotoxin (Ctx, Latoxan, Portes-lés-Valence, France), a snake
venom commonly used in vitro and in vivo to damage skeletal
muscle myoﬁbers and initiate a regeneration process, was used
to induce an injury on recellularized dECM. For these samples,
0.2 μM Ctx was added to the FM after 7 days of culture and it
was maintained for 6 hours [41]. Then samples were either
immediately ﬁxed and analyzed or maintained for 5 days in PM
and then analyzed.
RNA Extraction and Real Time PCR
Total RNAwas extracted using RNeasy PlusMini kit (Qiagen) follow-
ing the supplier’s instructions. RNA was quantiﬁed with a ND-2000
spectrophotometer and 1 μg was reverse transcripted with Super-
Script II and related products (all from Life Technologies), in a 20μl
reaction. Real-time Polymerase Chain Reaction (PCR) reactions
were performed using a LightCycler II (Roche, Basilea, Svizzerland).
Reactions have been carried out in duplicate using Platinum SYBR
Green qPCR SuperMix-UDG (Invitrogen) and 2 μl of primers mix
FW+REV (ﬁnal concentration, 300/300nM) in a ﬁnal volume of
20μl. Serial dilutions of a positive control sample were used to cre-
ate a standard curve for the relative quantiﬁcation. The amount of
each mRNA has been normalized for the content in β2-micro-
globulin. Primer sequences are listed in Supporting Information
Table S2.
Statistical Analyses
Data are expressed as mean SEM. For immunoﬂuorescence
and histological analyses, at least 15 random high-power ﬁeld
areas were considered per analyzed muscle. Statistical signiﬁ-
cance was determined using a nonparametric Kruskal–Wallis
test to analyze the variance followed by Dunn’s multiple com-
parison test to estimate the statistical difference between each
couple of groups. A p-value below .05 was considered statisti-
cally signiﬁcant. The data that support the ﬁndings of this
study are available from the corresponding author upon rea-
sonable request.
RESULTS
dECM Scaffold Characterization at Different Storage
Conditions
After decellularization, dECM scaffolds were stored for 2 weeks or
2 months in classic buffer (1× PBS +3% pen/strep) at 4C (2w4C
and 2m4C, respectively; n =9 for both conditions), or alternatively
in liquid nitrogen (2wLN and 2mLN, n =9 for both conditions) after
a slow-cooling protocol using DMSO as cryoprotectant. Histological
analysis was performed in order to examine the dECM integrity
after each storing condition (Fig. 1A). The 2m4C condition was the
worst in terms of ECM integrity preservation, as denucleated
myoﬁbers appeared desiccated and ruined, with an important
loss of muscle ﬁber structure and content. For this reason, this
experimental condition was excluded from subsequent analyses
together with 2wLN, that resulted macroscopically well-preserved
but, beside 2w4C storage, is less convenient and more expensive.
ECM component quantiﬁcations demonstrated that elastin and
collagen content was preserved in the stored samples, even though
longer stored scaffolds displayed a trend of increase in collagen per
milligrams of wet tissue, possibly due to minimal collagen crystalli-
zation during storage and subsequently increased solubility
(Fig. 1B, 1C). Although no signiﬁcant difference was detected in
sulfated GAG (sGAG) content in the two storing conditions, long-
term storage in liquid nitrogen (2mLN) showed lower sGAG
levels compared with freshly decellularized dECM (Fig. 1D). The
overall result of these analyses showed no difference in dECM
components between the two storage methods, but given the
faster and cheaper preservation, 2w4C stored samples were
used for successive recellulrization experiments. Also, electron
microscopy analysis conﬁrmed the occurred decellularization
and the good maintenance of myoﬁber’s structure after this
type of storage (Supporting Information Fig. S1A); 2mLN samples
were used to verify that recellularization is efﬁcient and not
impaired by a longer storage.
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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Human Pediatric MPC Isolation and Characterization
Similar to what we have previously demonstrated from adult
healthy muscle biopsies [34], pediatric hMPCs were isolated and
characterized in vitro for proliferative and differentiation abilities.
After isolation, cells were expanded until passage 5 (Fig. 2A, 2B)
in order to obtain a suitable number of cells for recellularization
experiments (between 5 and 7 million cells within 3weeks of
culture), and then analyzed for the expression of the speciﬁc
hMPC marker CD56 [34, 42, 43]. Only samples with at least 85%
of CD56+ cells were used in recellularization experiments (Fig. 2B).
We estimated the cell cycle length of the culture (i.e., doubling
time, 27.19hours 4.88 hours; Fig. 2C) and the expression of the
marker KI67 (52.62% 4.52%) in order to evaluate the cell prolif-
eration in vitro (Fig. 2D, 2E). In addition, cells expressing the myo-
genic markers PAX7 (21.50% 2.26%), MYF5 (64.02% 2.51%),
and MYOD (52.68% 3.08%) were quantiﬁed to better deﬁne
the skeletal muscle phenotype, commitment, and regenerative
potential of the isolated population (Fig. 2D, 2E). Cell differentia-
tion ability was assessed after induction of cell fusion, by staining
for myosin heavy chain (MYHC) and calculating the MI (0.51 
0.02), which demonstrated the maintenance of the differentiation
capacity also after expansion (Fig. 2F). Moreover, differentiated
cells demonstrated to be functionally activated since they respond
to ATP stimulus modulating calcium transients (Supporting Infor-
mation Movie S1). Being based on whole muscle digestion, the iso-
lation procedure gave rise to a heterogeneous cell population,
composed of myogenic cells and ﬁbroblasts, identiﬁed by the pres-
ence of TE7+ cells (ﬁbroblast marker, 22.50% 3.34%; Fig. 2E, 2G).
dECM Scaffold Recellularization and Device
Characterization
For the in vitro muscle generation, mouse decellularized dia-
phragms were divided in four parts discarding crural muscles
and obtaining patches (0.5 cm× 0.7 cm) of costal muscle only
Figure 1. Characterization of stored and not stored (fresh) mouse decellularized diaphragms. (A): Histological analyses of diaphragmatic
acellular scaffolds immediately after decellularization (fresh) or after different types and timings of storing: 2 weeks at 4C (2w4C),
2 months at 4C (2m4C), 2 weeks in liquid nitrogen (2wLN), and 2 months in liquid nitrogen (2mLN). HE stain for general appearance of
the muscle, MT for collagen, AB for GAG. Scale bar: 100 μm. (B–D): Elastin, collagen, and sGAG quantiﬁcations of decellularized dia-
phragms. Fresh decellularized samples were used as control. ***, p < .001. Scale bar: 100 μm. Abbreviations: HE, hematoxylin and eosin;
MT, Masson’s trichrome; AB, Alcian blue; GAG, glycosaminoglycans; sGAG, sulfated GAG; n.s., not signiﬁcant by Student’s t test.
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(Fig. 3A). The scaffolds were mounted on a rubber support with
pins, in order to both secure the dECM and stimulate a direc-
tional tension (Fig. 3B, 3D). Pilot experiments were done using
Evans blue dye instead of a cell suspension, to experience injec-
tion efﬁciency (Supporting Information Fig. S2 and Supporting
Information Movie S2). For recellularization experiments, pedi-
atric hMPCs were collected, resuspended in PGS, and injected
with a 33G needle into the dECM (Fig. 3C, 3D). PGS [40] was
chosen as cell vehicle because of its richness in cytokines and
growth factors [44, 45]. Recellularized scaffolds were analyzed
after 4, 7, and 12days of in vitro 3D culture. Human MPCs were
able to engraft, as demonstrated by histology, immunoﬂuores-
cence images (Fig. 3E, 3G and Supporting Information Fig. S3), and
by DNA amount quantiﬁed through Picogreen assay (Fig. 3E, 3H).
Comparable amount of DNA was detected after 7 days in culture in
respect to a fresh control diaphragm (Fig. 3H). Interestingly, a
homogeneous recellularization pattern was achieved also using
2mLN cryopreserved scaffolds (Supporting Information Fig. S4).
Human MPCs showed a tendency to maintain a similar cell
density among 4, 7, and 12days after seeding (Fig. 3I). As under-
lined by MT and ﬁbronectin stains (Fig. 3E, 3G and Supporting
Information Fig. S3), seeded cells were able to integrate within the
scaffold, but also to actively secrete ECM components identiﬁed
by ﬁbronectin around cells. This ECM deposition, easily observed
also by electron microscopy (Supporting Information Fig. S3B),
together with the area populated by the injected cells, was likely
to be responsible for the gradual increment of the scaffold thick-
ness from day 4 to day 12 (Fig. 3K). Importantly, we calculated the
cell distribution as the mean distance of farthest nuclei on the
total scaffold thickness, and obtained an increase from 60% at
4 days to more than 80% at 12days (Fig. 3J), with hMPCs able to
colonize the scaffold both inserting between and inﬁltrating de-
nucleated myoﬁbers (Fig. 3L and Supporting Information Fig. S1B).
dECM Scaffold Allows hMPC Proliferation and
Differentiation
Recellularized scaffolds were maintained in culture with PM for
4 days, thenmediumwas changed to FM to stimulate cell differenti-
ation and myotube formation, and PM was restored during the last
5 days of culture. According to this protocol, the highest percentage
of KI67+ proliferating cells was found after 4 days (10.20% 1.33%),
and then decreased in the later time points (1.52% 0.51% at
7 days; 3.63% 0.48% at 12days; Fig. 4A), conﬁrming that seeded
cells were able to respond microenvironment conditions. The num-
ber of PAX7+ cells remained similar among all the time points even
after stimulation by FM (18.99% 3.11% at 4 days; 16.70%
1.87% at 7 days; 16.62% 2.18% at 12days), suggesting themainte-
nance of stem cell pool in the construct (Fig. 4B). Myogenic progeni-
tor cell marker MYF5 was higher in the ﬁrst time point compared
with 7 and 12days of culture (Fig. 4C). On the contrary, the
expression of the differentiation marker α-sarcomeric actin
(ACTA), increased from day 4 to day 12, conﬁrming that also
the differentiation commitment was efﬁciently reproduced
in the engineered system (Fig. 4D and Supporting Information
Fig. S3). In addition, early and late myogenic markers were investi-
gated by real time PCR: as expected,MYF5 andMYODwere highly
expressed and continuously raised during the culture, highlighting
the presence of a proliferating, and early differentiating myogenic
Figure 2. Characterization of pediatric human muscle precursor cells (hMPCs) at passage 5 (p5). (A): PhC image of pediatric hMPCs in vitro.
(B): Histograms obtained from ﬂow cytometry analyses and representing the percentage of CD56+ cells (at p3 and p5). (C): Doubling
time (hours) of pediatric hMPCs. (D): Immunoﬂuorescence for KI67, PAX7, MYF5, and MYOD (in red); nuclei are counterstained with HOECHST
(in blue). (E): Quantiﬁcations of KI67+, PAX7+, MYF5+, MYOD+, and TE7+ cells. (F): Immunoﬂuorescence after hMPCs differentiation. MYHC
is shown in red and nuclei in blue (counterstained with HOECHST). Myogenic index of pediatric hMPCs in vitro at p5. (G): Immunoﬂuores-
cence for TE7 (in red); nuclei are counterstained with HOECHST (in blue). All scale bars: 100μm. Abbreviation: PhC, phase contrast.
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population (Fig. 4E). Late differentiation markers MYHC and DYS-
TROPHIN (DYSTR) weremore expressed at day 7 and 12 compared
with day 4 (Fig. 4F). Mature skeletal muscle proteins were also
investigated through Western blot, demonstrating the presence
of both newly formed (MYH3) and mature (MYHC) myoﬁbers
inside the recellularized dECM after 7 days in culture (Fig. 4G).
Given the strong expression of functional skeletal muscle markers,
we investigated the maturity of regenerated myoﬁbers inside
the construct by analyzing calcium transient. Starting from 7 days
of in vitro culture, our device showed to possess functioning
myotubes able to answer to ATP stimulation with a fast and syn-
chronous transient in cytosolic calcium concentration (Fig. 4H and
Supporting Information Movie S3). All these results demonstrated
that hMPCs were able to grow and functionally differentiate when
seeded in a decellularized skeletal muscle tissue maintaining an
intact stem cell pool at the same time.
The Construct Responds to Cardiotoxin Injury
To test the device regeneration potential in vitro, we dam-
aged the construct with Ctx at 7 days of culture and analyzed
its response 6 hours and 5 days after injury. The aim was to
investigate the ability of the population of PAX7+ cells to be
activated and regenerate the damaged tissue as it happens
physiologically in vivo. After injury, we found an increase of
KI67+ cells (threefold) only 5 days after injury (Fig. 5A), whereas
at both 6 hours and 5 days, PAX7+ cells raised in respect to un-
injured control (3.4-fold and 4.4-fold, respectively; Fig. 5B).
Interestingly, cells coexpressing PAX7 and KI67 were found
greatly increased 5 days after injury (14-fold more than un-
injured samples, Fig. 5C, 5D), conﬁrming the presence of a func-
tional stem cell pool preserving physiological features inside the
construct. These results were conﬁrmed also by molecular biol-
ogy analyses in which we found an overexpression of PAX7 and
MYF5 transcripts 5 days after Ctx injury in respect to 6 hours
injured samples and 7 days uninjured control (Fig. 5D). More-
over, 5 days after injury, the graft was able to regenerate and to
produce new skeletal muscle tissue since we found a regain of
MYHC gene expression and several MYHC and ACTA positive
myotubes (Fig. 5E, 5F). Also LAMA1, a gene responsible of stem
cell niche reconstitution and basal lamina production after dam-
age was overexpressed after Ctx injury in respect to 7-days
uninjured control, and its upregulation gradually decreased dur-
ing the days following the injury (Fig. 5G), as described in the
literature [46]. Together with production of new basal lamina
components, regenerating satellite cells are able to transiently
remodel their niche producing the ECM glycoprotein ﬁbronectin
[47]. In our device, 5 days after Ctx injury there was an
increased production of ﬁbronectin (Fig. 5G), conﬁrming the
Figure 3. Recellularization procedure and characterization of recellularized diaphragmatic scaffolds. (A): Left: entire decellularized dia-
phragm. Right: four sections (50mm2 each) obtained from the entire decellularized diaphragm after the removal of the crural muscle.
(B): Positioning of the decellularized scaffolds on the rubber support. The scaffolds were ﬁxed with four pins following the ﬁbers orienta-
tion. (C): Representative image describing the injection procedure. (D): Left: positioning of the rubber support with recellularized scaffolds
on a well of a 6-wells plate. Right: medium addition. (E): Masson’s trichrome staining for recellularized diaphragms after 7 days of culture.
(F): Immunoﬂuorescence of the recellularized samples showing hMPCs engraftment. Laminin (green) and nuclei counterstained with DAPI
(blue). (G): Immunoﬂuorescence of laminin and ﬁbronectin (red). Nuclei were counterstained with DAPI. Scale bars: 100 μm. (H): DNA
amount before (dECM) and after (7d) recellularization calculated with Picogreen assay. (I): Recellularized scaffold cell density (cells per
mm2) at different time points (cell density was calculated dividing the number of cells for the area of the diaphragm). (J): Cell distribution
on recellularized samples. Hundred percentage is the full thickness of the decellularized scaffold. (K): Scaffold thickness before
recellularization (dECM) and after 4, 7, and 12 days of culture from cell injection. (L): Electron microscopy of recellularized scaffold after
7 days in culture. Upper image: myogenic cell inﬁltrating an old de-nucleated ﬁber; lower image: myogenic cell inserting between two
adjacent decellularized ﬁbers. *, p < .05; **, p < .01. Abbreviations: C, cell; dECM, diaphragm-derived extracellular matrix; f, ﬁber; hMPCs,
human muscle precursor cells; n.s., not signiﬁcant by Student’s t test.
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ability of engrafted PAX7+ cells to regenerate the muscle-like
construct by modulating their behavior and environment.
To verify that the stem cell pool is maintained also in a more
mature construct and that regeneration process is able to be acti-
vated distantly from the initial cell seeding, we decided to damage
the construct with Ctx 21days after recellularization, and to analyze
the percentage of PAX7+ cells 5days after injury. In this longer time
point, the construct expressed functional muscle proteins such as
MYH3, Desmin, and Dystrophin (Supporting Information Fig. S5A)
more strongly than after 7 and 12days of culture. Interestingly, also
in this mature construct, the percentage of PAX7+ cells increased by
the same fold (approximately 3) after Ctx treatment (Supporting
Information Fig. S5B), emphasizing that the regenerative potential of
engrafted stem cells remained unalteredwhen cultured on dECM.
DISCUSSION
Engineering skeletal muscle for the therapy remains a chal-
lenge. In this work, we demonstrated the ability of hMPCs to
repopulate a decellularized dECM scaffold and to generate
in vitro a self-renewing device, as proof of principle for future
preclinical and clinical studies. The aim was to identify the best
technique to recreate in vitro diaphragmatic muscle tissues
combining a natural derived-ECM and patient speciﬁc progeni-
tor cells, in order to obtain possible substitutes for diaphragm
muscle diseases.
When designing a construct to be used in a clinical setting, it is
important to develop a feasible and effective storage method that
allows the scaffold to be preserved in the manufacturing facility
and made rapidly available to the clinicians as an off-the-shelf
product. This is a critical step and would allow widening clinical
applications of tissue engineered products to more emergency
situations [12]. Despite the literature, several research papers
reported the scaffold storage after lyophilization [48–50], our aim
was to preserve dECM structure and architecture also after storage
without the need for swelling procedure, to obtain in vitro a con-
struct as similar as possible to the original muscle. Giving that
dECM was preserved in a better condition when stored for a short
Figure 4. Immunoﬂuorescence, quantiﬁcations, and molecular biology analyses of early and late myogenic markers. (A): Representative
immunoﬂuorescence images of recellularized samples after 7 days. KI67 (red), laminin (green), and nuclei counterstained with DAPI
(blue). Quantiﬁcations were done at days 4, 7, and 12. (B): Immunoﬂuorescence of satellite cells marker PAX7 (red) and related quantiﬁ-
cations. (C): Immunoﬂuorescence and quantiﬁcations of the early myogenic marker MYF5 (red). (D): Immunoﬂuorescence and quantiﬁca-
tion of the late myogenic marker ACTA (red). (E): Molecular biology analyses (real time PCR) at 4, 7, and 12 days of early myogenic
markers MYF5 and MYOD. (F): Molecular biology analyses of late myogenic markers MYHC and DYSTR. (G): Western blot analyses of
mature myogenic proteins. GAPDH was used as human speciﬁc cell marker, laminin as extracellular matrix control. (H): Representative
images of recellularized samples after 7 days in culture with myotubes loaded with the calcium dye Fluo-4 AM and stimulated by ATP
application. Graphics show mean ﬂuorescence intensity (ΔF/F0) of the Region of Interests depicted. All scale bars: 100 μm. *, p < .05; **,
p < .01; ***, p < .001; n.s., not signiﬁcant by Mann–Whitney U test.
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period or using a cryoprotectant for longer time, as it happens for
other biologic-derived scaffolds [51], it means that this product can
be treated as a fresh and viable tissue, and that standard GMP stor-
age rules could be applied also to dECM [52]. Nevertheless, the
scaffolds used in this study were from rodents that, together with
other important manufacturing issues (i.e., decontamination and
sterilization), should be reconsidered before a possible clinical
translation, possibly moving to the use of large animal model or
human tissue samples [53].
We have previously described that decellularized dECM
triggers myogenic cell activation and skeletal muscle regener-
ation when implanted in vivo, both in wild and atrophic
mouse models [31]. Preclinical studies with in vivo application
of decellularized matrices for skeletal muscle regeneration
demonstrated a similar positive remodeling process, such as
scaffold degradation by host cells, vascularization, and recruit-
ment of stem/progenitor cells to the site of implantation [7,
8, 31, 54]. In previous studies, despite the presence of new
muscle ﬁbers in the treated area, none of the experiments
succeeded in mimicking the precise organization of the native
muscle [54–56]. This is probably due to the lack of speciﬁc sig-
nals toward regeneration inside the implanted dECM [57],
especially when used to repair large muscle defects, an impor-
tant aspect not only in the tissue regeneration after damage
or loss of muscle volume, but also in the treatment of skeletal
muscle congenital defects such as CDH. This limitation high-
lights the need for alternative scaffolds capable to boost
myoﬁber generation to improve tissue functionality. Bioscaffolds
engineered with cells are an option to overcome the limitations
related to the use of acellular matrix alone [58], increasing ate
the same time healing process and the better clinical outcome.
In this view, we were able to produce a viable and func-
tional construct generated by the combination of animal-
derived dECM and human muscle progenitor cells. Up to now, a
variety of tissue engineering strategies have been described to
develop 2D and 3D skeletal muscle constructs, employing vari-
able scaffold materials and cell types [5, 41, 59–63]. Neverthe-
less, the in vitro generation of a skeletal muscle construct
Figure 5. Characterization of recellularized samples after Ctx injury. (A): Immunoﬂuorescence and quantiﬁcations of KI67+ cells (red).
Laminin (green) and nuclei counterstained with DAPI (blue). (B): Immunoﬂuorescence images and quantiﬁcations for PAX7+ cells (red).
(C): Costaining for PAX7+ (red) and KI67+ (green) cells, nuclei colored with DAPI and related quantiﬁcations. Quantiﬁcations were normal-
ized on noninjured 7 days samples. (D): Molecular biology analyses (real time PCR) of PAX7 and MYF5 at 7 days and 6 hours or 5 days
after Ctx injury. (E): Representative immunoﬂuorescence images of ACTA (on the top) and MYHC (on the bottom) for the Ctx + 5d sample.
Laminin (green) and nuclei counterstained with DAPI. (F): Transcription of MYHC at 7 days and 6 hours or 5 days after Ctx injury. (G):
Molecular biology analysis of LAMA1 expression at 7 days and 6 hours or 5 days after Ctx injury and representative immunoﬂuorescent
image of ﬁbronectin production in uninjured samples (no Ctx) and 5 days after Ctx injury. Laminin (green) and nuclei counterstained with
DAPI. All scale bars: 100 μm. ***, p < .001.
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with structural and functional characteristics comparable to the
native tissue is still a major challenge. One of the most impor-
tant features in the development of an engineered tissue is the
choice of the best cell type. Cell sources for therapeutic implan-
tation include embryonic stem cells (ESCs), induced-pluripotent
stem cells (iPSCs), fetal, and adult muscle stem cells, as well as
lineage-committed cell types. ESCs and iPSCs are an attractive
option because they can be expanded in vitro and induced to
commit toward different lineages, including myogenic progeni-
tors [64–67]. However, they are still far from clinical use
because several aspects still limit their application, such as the
ethical problems related to the use of ESCs, the possibility of an
immune response against nonautologous and exogenous cells, and
the difﬁculty in the commitment toward muscle cells that must be
strongly induced through the use of viral vectors. For all these rea-
sons, we focused our attention directly on tissue speciﬁc and possi-
bly autologous progenitors. Human MPCs are able to grow in vitro
for several passages, allowing cell expansion for both graft genera-
tion and standard cell quality controls [34]. Importantly, with our
cell isolation protocol, a population of ﬁbroblasts grows together
with muscle cells. This is an important aspect, since other authors
demonstrated that ﬁbroblasts improve scaffold regeneration and
myogenesis when seeded into the acellular tissue together with
muscle cells [8, 68]. In addition, within isolated hMPCs there is a
subpopulation of PAX7+ stem cells that allows the culture to self-
renew under appropriate conditions [69]. Several studies have
shown that, compared with differentiated or committed cells,
undifferentiatedmuscle stem cells are amore potent myogenic cell
source, with the ability to engraft and replenish the host satellite
cell pool and support future rounds of muscle regeneration [62, 70,
71]. It is therefore believed that for optimal results in engineering
muscle tissues, cellular heterogeneity of native muscle should
be recreated together with both force-generating, differentiated
myoﬁbers, and functioning stem cells to allow further maturation
and regeneration prior and after implantation [58]. In our experi-
ments, we demonstrated that hMPCs were able to engraft in the
scaffold, proliferate, and repopulate all the layers of the dECM, also
interacting with the scaffold and responding to external stimuli. In
the device, hMPCs expressing MYF5, the ﬁrst factor responsible of
the skeletal muscle lineage speciﬁcation in vivo [72], are more sen-
sible to microenvironmental changes, modulating the expression
of this marker based on the presence of proliferating or differenti-
ating culture media. Transcription of the skeletal muscle program is
then achieved by the subsequent expression ofMYOD that in turn
activates the expression and production of mature skeletal muscle
genes and proteins. Indeed, when induced to differentiate,
engrafted cells started expressing speciﬁc differentiation markers
such as ACTA and MYHC. Among all these late myogenic markers,
there is also MYH3, a protein exclusively present in developing
myoﬁbers [73] that conﬁrms the activation of the entire myogenic
program. Moreover, the 3D construct demonstrated to be func-
tioning in vitro and with metabolic active myotubes inside the
dECM, a mandatory feature to deﬁne a recellularized scaffold as a
tissue-like construct.
The engineered muscle must be able also to respond physiologi-
cally to damage and remodeling. When we damaged the scaffold
with Ctx, mimicking the injury classically used in vivo to stimulate
muscle regeneration, PAX7+ engrafted cells increased in number and
then generated a population of committed cells that fused together
forming newmyoﬁbers, suggesting that seeded stem cells were able
to recreate a well-structured and organized tissue.Most importantly,
they were able to regenerate the stem cell niche, as demonstrated
by the increased expression of LAMA1 and the production of ﬁbro-
nectin which, upon activation of PAX7+ cells bymeans of a Ctx injury,
are indicative of the stem niche remodeling and fundamental events
in themechanism of self-renewalmaintenance [46, 47].
The possibility to generate a functional skeletal muscle
graft in vitro opens new therapeutic options for the treatment
of several defects that require muscle replenishment or substi-
tution. Although decellularized matrices can promote regener-
ation for volumetric skeletal muscle loss [7, 8], they are
associated to high failure rate when used to repair large defects
[74]. The latter is a big concern in pediatric surgery, where con-
genital malformations, such as CDH, do not have a standardized
and deﬁnitive techniques for defect repair [75, 76]. Hence, the
development of a tissue engineered construct combining autol-
ogous MPCs from pediatric specimens with a storable biological
scaffold deprived of antigenic response, would represent a clini-
cally attractive option for patient-speciﬁc therapies. Further-
more, in vivo studies will investigate the efﬁcacy of this muscle
construct in the repair of diaphragmatic hernia, especially con-
sidering the interaction between seeded and resident cells and
the ability to attract vessels and trigger innervation to the site
of regeneration. At the same time, such skeletal muscle device
could be used in vitro for drug testing and screening, since it
could be assimilated to a viable and functional skeletal muscle
tissue obtained from speciﬁc patients for which tailored thera-
peutic drugs and dosage are desirable. Furthermore, experi-
ments are needed to test different possible culture conditions
(e.g., oxygen tension, mechanical stimuli, dynamic culture)
and to optimize cell engraftment, adding, and implementing
the recellularization with other important cell types such as
macrophages, endothelial, and neural cells, to obtain a more
complete in vitro xenograft for possible preclinical and clini-
cal applications.
CONCLUSION
In the present work, a storable and ready-to-use dECM was
used as cell support to generate a self-renewing skeletal mus-
cle construct, as a combination of a mouse-derived ECM and
human progenitor cells. We believe that this work represents
a step forward toward the generation of tissue engineering
xenograft for skeletal muscle clinical applications. As previ-
ously demonstrated for the trachea [12], we believe tissue
engineered skeletal muscle could be beneﬁcial for the treat-
ment of CDH.
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